Efficacy and Tolerability of Topical Trifarotene in Managing Acne Vulgaris Among Malaysians

BACKGROUNDTrifarotene is a new fourth-generation topical retinoid that selectively binds to RAR-γ receptors. However, the efficacy and safety data of trifarotene on Asians are lacking. Thus, we evaluated its real-world efficacy and tolerability among Malaysians.

METHODSThis prospective, 12-week observational study at Hospital Sultan Abdul Aziz Shah, Malaysia, involved participants with mild-to-moderate facial acne. Efficacy was assessed using absolute lesion counts, Investigator's Global Assessment (IGA), Post-Acne Hyperpigmentation Index (PAHPI), and Cardiff Acne Disability Index (CADI). Tolerability was evaluated by using a modified safety assessment scale and participant-reported side effects. Participants' satisfaction and subjective outcomes were assessed via a questionnaire at week 12.

RESULTS21 participants completed the study. A significant reduction of acne lesions was observed at week 12 (p < 0.05). Treatment success rate was achieved in 61.9%, with significant improvement in PAHPI and CADI scores (p < 0.05). By week 12, 61.9% of participants experienced no irritation. Common side effects included dryness (81.0%), burning sensation (71.4%) and erythema (52.4%). Most participants were satisfied with the outcomes (85.7%), and willing to continue and recommend it to others (81.0%).

CONCLUSIONTrifarotene demonstrated significant efficacy and good tolerability supporting its use as a valuable option for acne management in Malaysia.

Abstract from Crossref